

Helen Colhoun

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6388865/helen-colhoun-publications-by-year.pdf>

Version: 2023-12-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

257
papers

19,191
citations

66
h-index

134
g-index

269
ext. papers

22,888
ext. citations

9.4
avg, IF

6.33
L-index

#	Paper	IF	Citations
257	Flash monitor initiation is associated with improvements in HbA levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. <i>Diabetologia</i> , 2022 , 65, 159-172	10.3	2
256	Effect of serum sample storage temperature on metabolomic and proteomic biomarkers.. <i>Scientific Reports</i> , 2022 , 12, 4571	4.9	2
255	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-6	1.9	1
254	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. <i>Diabetes Care</i> , 2021 ,	14.6	6
253	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. <i>Diabetes Care</i> , 2021 , 44, 390-398	14.6	18
252	Genome-Wide Association Study of Peripheral Artery Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e002862	5.2	3
251	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021 , 42, 2565-2573	9.5	7
250	Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. <i>Archives of Disease in Childhood</i> , 2021 , 106, 1212-1217	2.2	12
249	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021 , 64, 1320-1331	10.3	9
248	Sodium-Glucose Co-Transporter β Inhibitors (SGLT2i) Exposure and Outcomes in Type β Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 991-1028	3.6	8
247	Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1371-1378	6.7	3
246	Microvascular disease in diabetes and severe COVID-19 outcomes - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 201	18.1	
245	Insulin resistance-associated genetic variants in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107842	3.2	4
244	Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin. <i>Diabetologia</i> , 2021 , 64, 1725-1736	10.3	2
243	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> 2021;44:901-907. <i>Diabetes Care</i> , 2021 , 44, e140-e141	14.6	1
242	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021 , 19, 149	11.4	10
241	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 2001-2011	10.3	3

240	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021 , 44, 2010-2017	14.6	4
239	Reservoir-Excess Pressure Parameters Independently Predict Cardiovascular Events in Individuals With Type 2 Diabetes. <i>Hypertension</i> , 2021 , 78, 40-50	8.5	2
238	mutation alters immune system activation, inflammation, and risk of autoimmunity. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1332-1340	5	4
237	Quantitative levels of serum N-glycans in type 1 diabetes and their association with kidney disease. <i>Glycobiology</i> , 2021 , 31, 613-623	5.8	1
236	Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2021 , 70, 986-995	0.9	2
235	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 82-93	18.1	112
234	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021 , 19, 51	11.4	14
233	Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type-2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 969-989	3.6	1
232	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 1309-1319	10.3	1
231	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 484-490	18.1	2
230	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. <i>Cardiovascular Diabetology</i> , 2021 , 20, 194	8.7	4
229	Effect of Vaccination on Transmission of SARS-CoV-2. <i>New England Journal of Medicine</i> , 2021 , 385, 1718-1720	37.20	54
228	Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study. <i>BMJ, The</i> , 2021 , 374, n2060	5.9	9
227	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 901-907	14.6	5
226	Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland.. <i>BMC Infectious Diseases</i> , 2021 , 21, 1275	4	1
225	Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. <i>Diabetes Care</i> , 2020 , 43, 734-742	14.6	7
224	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004-2017. <i>Diabetologia</i> , 2020 , 63, 1626-1636	10.3	4
223	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , 2020 , 19, 582-590	24.1	48

222	Socio-economic differences in cardiovascular disease risk factor prevalence in people with type 2 diabetes in Scotland: a cross-sectional study. <i>Diabetic Medicine</i> , 2020 , 37, 1395-1402	3.5	2
221	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland. <i>Diabetes Care</i> , 2020 , 43, 2034-2041	14.6	5
220	Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. <i>Science Advances</i> , 2020 , 6, eaax0301	14.3	38
219	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020 , 19, 14	8.7	12
218	The cost of prevalent and incident cardiovascular disease in people with type 2 diabetes in Scotland: data from the Scottish Care Information-Diabetes Collaboration. <i>Diabetic Medicine</i> , 2020 , 37, 1927-1934	3.5	0
217	356-OR: Effect of Dulaglutide on Kidney Function Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. <i>Diabetes</i> , 2020 , 69, 356-OR	0.9	2
216	924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. <i>Diabetes</i> , 2020 , 69, 924-P	0.9	1
215	490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial. <i>Diabetes</i> , 2020 , 69, 490-P	0.9	0
214	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. <i>Diabetologia</i> , 2020 , 63, 788-798	10.3	13
213	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 106-114	18.1	42
212	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. <i>Diabetologia</i> , 2020 , 63, 636-647	10.3	10
211	The effect of DAFNE education, continuous subcutaneous insulin infusion, or both in a population with type 1 diabetes in Scotland. <i>Diabetic Medicine</i> , 2020 , 37, 1016-1022	3.5	5
210	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , 2020 , 17, e1003374	11.6	36
209	Socio-economic status and mortality in people with type 1 diabetes in Scotland 2006-2015: a retrospective cohort study. <i>Diabetic Medicine</i> , 2020 , 37, 2081-2088	3.5	6
208	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020 , 229, 61-69	4.9	53
207	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 199	8.7	3
206	Diabetes in Scotland: a rising tide. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 375-376	18.1	0
205	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. <i>BMJ, The</i> , 2020 , 371, m3582	5.9	153

204	Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes. <i>Pediatric Diabetes</i> , 2020 , 21, 1322-1332	3.6	1
203	Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e002769	5.2	1
202	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
201	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
200	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
199	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
198	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study 2020 , 17, e1003374		
197	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. <i>BMC Medicine</i> , 2019 , 17, 165	11.4	20
196	Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. <i>Diabetologia</i> , 2019 , 62, 418-425	10.3	15
195	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019 , 393, 407-415	40	300
194	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1907-1924	3.8	6
193	Biomarker panels associated with progression of renal disease in type 1 diabetes. <i>Diabetologia</i> , 2019 , 62, 1616-1627	10.3	19
192	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 121-130	40	917
191	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 131-138	40	228
190	Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016. <i>Diabetologia</i> , 2019 , 62, 1375-1384	10.3	25
189	Factors associated with stillbirth in women with diabetes. <i>Diabetologia</i> , 2019 , 62, 1938-1947	10.3	19
188	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 618-628	18.1	120
187	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. <i>PLoS Medicine</i> , 2019 , 16, e1002945	11.6	7

186	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150mg doses. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 979-988.e10	4.9	9
185	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2000-2016	12.7	66
184	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019 , 18, 149	8.7	13
183	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019 , 62, 621-632	10.3	21
182	Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. <i>Diabetes</i> , 2019 , 68, 441-456	0.9	31
181	Serum kidney injury molecule 1 and β microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. <i>Diabetologia</i> , 2019 , 62, 156-168	10.3	27
180	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. <i>Diabetic Medicine</i> , 2019 , 36, 718-725	3.5	26
179	Biomarkers of diabetic kidney disease. <i>Diabetologia</i> , 2018 , 61, 996-1011	10.3	105
178	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018 , 93, 1397-1408	9.9	50
177	Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies. <i>International Journal of Epidemiology</i> , 2018 , 47, 617-624	7.8	20
176	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1479-1489	6.7	63
175	Diabetes and pregnancy: national trends over a 15year period. <i>Diabetologia</i> , 2018 , 61, 1081-1088	10.3	69
174	Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 31	2.3	26
173	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1414-1427	0.9	71
172	Development and Validation of a Path Length Calculation for Carotid-Femoral Pulse Wave Velocity Measurement: A TASCFORCE, SUMMIT, and Caerphilly Collaborative Venture. <i>Hypertension</i> , 2018 , 71, 937-945	8.5	12
171	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. <i>Diabetic Medicine</i> , 2018 , 35, 99-106	3.5	11
170	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012-2014): a population-based observational study. <i>Diabetologia</i> , 2018 , 61, 108-116	10.3	29
169	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018 , 138, 2774-2786	16.7	78

168	Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study. <i>Diabetes Care</i> , 2018 , 41, 2212-2219	14.6	18
167	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. <i>Atherosclerosis</i> , 2018 , 276, 124-130	3.1	18
166	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. <i>Diabetes Care</i> , 2018 , 41, 2010-2018	14.6	26
165	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). <i>International Journal of Epidemiology</i> , 2018 , 47, 380-381j	7.8	37
164	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 42-49	6.7	121
163	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018 , 41, 341-347	14.6	56
162	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 79-87	14.6	43
161	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004724	5.8	27
160	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018 , 392, 1311-1320	40	208
159	A genome-wide association study suggests new evidence for an association of the NADPH Oxidase 4 (NOX4) gene with severe diabetic retinopathy in type 2 diabetes. <i>Acta Ophthalmologica</i> , 2018 , 96, e811-e819 ³⁶	3.7	36
158	Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. <i>Atherosclerosis</i> , 2018 , 274, 182-190	3.1	5
157	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018 , 9, 1317-1334	3.6	18
156	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 597-609 ^{18,1}	18.1	177
155	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. <i>Diabetes and Metabolism</i> , 2017 , 43, 453-459	5.4	12
154	Automated pathway and reaction prediction facilitates in silico identification of unknown metabolites in human cohort studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017 , 1071, 58-67	3.2	10
153	Metformin in adults with type 1 diabetes: Design and methods of REducing with MetFOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 509-516	6.7	24
152	Modelling cumulative exposure for inference about drug effects in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1527-1533	2.6	6
151	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. <i>Cardiovascular Diabetology</i> , 2017 , 16, 114	8.7	20

150	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1781-1792	6.7	84
149	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	11
148	A genome-wide association study suggests that MAPK14 is associated with diabetic foot ulcers. <i>British Journal of Dermatology</i> , 2017 , 177, 1664-1670	4	20
147	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 986-997	4.9	17
146	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). <i>American Journal of Cardiology</i> , 2017 , 120, 931-939	3	20
145	Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10,		2
144	Effects of inaccuracies in arterial path length measurement on differences in MRI and tonometry measured pulse wave velocity. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 118	2.3	11
143	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017 , 16, 70	8.7	21
142	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 557-574	12.7	69
141	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017 , 38, 3569-3575	9.5	25
140	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). <i>International Journal of Epidemiology</i> , 2017 , 46, 796-796i	7.8	15
139	Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	59
138	Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 171	2.3	9
137	Whole body cardiovascular magnetic resonance imaging to stratify symptomatic and asymptomatic atherosclerotic burden in patients with isolated cardiovascular disease. <i>BMC Medical Imaging</i> , 2016 , 16, 18	2.9	6
136	Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). <i>Diabetologia</i> , 2016 , 59, 299-306	10.3	25
135	A Genome-Wide Association Study Provides New Evidence That CACNA1C Gene is Associated With Diabetic Cataract 2016 , 57, 2246-50		10
134	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. <i>Journal of Medical Genetics</i> , 2016 , 53, 835-845	5.8	28
133	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9, 213-21	5.8	8

132	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. <i>Atherosclerosis</i> , 2016 , 244, 138-46	3.1	150
131	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016 , 37, 2981-2989	9.5	108
130	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. <i>Diabetologia</i> , 2016 , 59, 2106-13	10.3	58
129	Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. <i>Diabetic Medicine</i> , 2016 , 33, 886-95	3.5	9
128	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 1186-94	9.5	289
127	Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. <i>Diabetologia</i> , 2015 , 58, 1363-71	10.3	47
126	Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. <i>Kidney International</i> , 2015 , 88, 888-96	9.9	91
125	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. <i>Diabetologia</i> , 2015 , 58, 1494-502	10.3	23
124	Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. <i>Diabetologia</i> , 2015 , 58, 716-25	10.3	18
123	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015 , 36, 1536-46	9.5	88
122	Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1723-31	9.4	66
121	End-stage renal disease and survival in people with diabetes: a national database linkage study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015 , 108, 127-34	2.7	32
120	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. <i>Diabetologia</i> , 2015 , 58, 493-504	10.3	114
119	A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. <i>European Journal of Pain</i> , 2015 , 19, 392-9	3.7	58
118	15 Epicardial fat in diabetes mellitus and cardiovascular disease measured using cardiac magnetic resonance imaging: a summit substudy. <i>Heart</i> , 2015 , 101, A5.3-A6	5.1	
117	A Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) With Diabetic Neuropathic Pain. <i>EBioMedicine</i> , 2015 , 2, 1386-93	8.8	55
116	Cohort comparison study of cardiac disease and atherosclerotic burden in type 2 diabetic adults using whole body cardiovascular magnetic resonance imaging. <i>Cardiovascular Diabetology</i> , 2015 , 14, 122	8.7	13
115	Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study. <i>Journal of Internal Medicine</i> , 2015 , 278, 291-302	10.8	29

114	Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 37-44	27.4	326
113	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , 2015 , 169, 906-915.e13	4.9	251
112	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. <i>Lancet, The</i> , 2015 , 385, 1397-405	40	756
111	LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. <i>Diabetes Care</i> , 2014 , 37, 1643-9	14.6	49
110	Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1054-60	6.3	91
109	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 485-94	15.1	372
108	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014 , 176, 55-61	3.2	204
107	Characterizing genetic variants for clinical action. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014 , 166C, 93-104	3.1	41
106	Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. <i>Clinical Cardiology</i> , 2014 , 37, 597-604	3.3	36
105	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014 , 5, 5068	17.4	160
104	Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. <i>British Journal of Ophthalmology</i> , 2014 , 98, 790-5	5.5	49
103	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <i>BMC Cardiovascular Disorders</i> , 2014 , 14, 121	2.3	40
102	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. <i>Lancet Diabetes and Endocrinology, the</i> , 2014 , 2, 481-7	18.1	76
101	Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. <i>Diabetologia</i> , 2014 , 57, 260-1	10.3	1
100	Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness. <i>Health Technology Assessment</i> , 2014 , 18, 1-128	4.4	26
99	Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001-2007. <i>Diabetologia</i> , 2013 , 56, 1712-5	10.3	10
98	Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. <i>Diabetologia</i> , 2013 , 56, 1716-25	10.3	54
97	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. <i>Diabetologia</i> , 2013 , 56, 1845-55	10.3	34

96	Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?. <i>Diabetologia</i> , 2013 , 56, 1462-70	10.3	127
95	Cause-specific mortality in Scottish patients with colorectal cancer with and without type 2 diabetes (2000-2007). <i>Diabetologia</i> , 2013 , 56, 1531-41	10.3	14
94	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. <i>Circulation</i> , 2013 , 128, 1504-12	16.7	135
93	Common variants in Mendelian kidney disease genes and their association with renal function. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 2105-17	12.7	27
92	Investigation of known estimated glomerular filtration rate loci in patients with type 2 diabetes. <i>Diabetic Medicine</i> , 2013 , 30, 1230-5	3.5	26
91	Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. <i>Cardiovascular Diabetology</i> , 2013 , 12, 149	8.7	36
90	Ethnic differences in glycaemic control in people with type 2 diabetes mellitus living in Scotland. <i>PLoS ONE</i> , 2013 , 8, e83292	3.7	24
89	Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. <i>Diabetologia</i> , 2012 , 55, 2929-37	10.3	110
88	Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. <i>Diabetologia</i> , 2012 , 55, 2938-45	10.3	40
87	Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. <i>Diabetologia</i> , 2012 , 55, 2335-42	10.3	62
86	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. <i>Diabetologia</i> , 2012 , 55, 2356-60	10.3	29
85	Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. <i>PLoS ONE</i> , 2012 , 7, e39362	3.7	66
84	Genome-wide association and functional follow-up reveals new loci for kidney function. <i>PLoS Genetics</i> , 2012 , 8, e1002584	6	143
83	Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. <i>PLoS Medicine</i> , 2012 , 9, e1001321	11.6	208
82	New susceptibility loci associated with kidney disease in type 1 diabetes. <i>PLoS Genetics</i> , 2012 , 8, e1002921	6	176
81	Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. <i>Human Molecular Genetics</i> , 2012 , 21, 5329-43	5.6	54
80	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1302-9	27.4	512
79	Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). <i>Journal of Lipid Research</i> , 2012 , 53, 1000-1011	6.3	79

78	Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study. <i>Diabetes Care</i> , 2012 , 35, 2588-90	14.6	80
77	Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1535-45	15.1	259
76	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011 , 43, 117-20	36.3	319
75	Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 210-6	6.1	153
74	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2011 , 54, 2000-8	10.3	23
73	Do men develop type 2 diabetes at lower body mass indices than women?. <i>Diabetologia</i> , 2011 , 54, 3003-6	10.3	173
72	Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetes Care</i> , 2011 , 34, 1992-7	14.6	27
71	The effect of atorvastatin therapy on tumour necrosis factor- α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2011 , 11, 288-297		
70	Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. <i>Diabetes</i> , 2011 , 60, 2379-85	0.9	125
69	Effect of socioeconomic status on mortality among people with type 2 diabetes: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetes Care</i> , 2011 , 34, 1127-32	14.6	58
68	The use of metformin in type 1 diabetes: a systematic review of efficacy. <i>Diabetologia</i> , 2010 , 53, 809-20	10.3	138
67	Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Clinical Chemistry</i> , 2009 , 55, 473-80	5.5	65
66	Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). <i>American Journal of Kidney Diseases</i> , 2009 , 54, 810-9	7.4	189
65	Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2009 , 52, 1755-65	10.3	301
64	The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 177-83	3.3	33
63	Antibodies to periodontal pathogens and coronary artery calcification in type 1 diabetic and nondiabetic subjects. <i>Journal of Periodontal Research</i> , 2008 , 43, 103-10	4.3	17
62	Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. <i>Diabetologia</i> , 2008 , 51, 1639-45	10.3	41
61	Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetologia</i> , 2007 , 50, 733-40	10.3	33

60	Lipid goals in metabolic syndrome and diabetes. <i>Current Atherosclerosis Reports</i> , 2007 , 9, 286-95	6	2
59	Eicosapentaenoic acid for prevention of major coronary events. <i>Lancet, The</i> , 2007 , 370, 215	40	
58	All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. <i>Diabetologia</i> , 2006 , 49, 660-6	10.3	167
57	Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. <i>Diabetologia</i> , 2006 , 49, 2859-65	10.3	75
56	Treatment of lipid disorders in patients with diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006 , 8, 37-45	2.1	5
55	Coronary heart disease in women: why the disproportionate risk?. <i>Current Diabetes Reports</i> , 2006 , 6, 22-8;6		12
54	Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetes Care</i> , 2006 , 29, 2378-84	14.6	87
53	Insight into the nature of the CRP-coronary event association using Mendelian randomization. <i>International Journal of Epidemiology</i> , 2006 , 35, 922-31	7.8	137
52	High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. <i>Diabetes Care</i> , 2006 , 29, 798-804	14.6	267
51	Mortality in people with type 2 diabetes in the UK. <i>Diabetic Medicine</i> , 2006 , 23, 516-21	3.5	149
50	After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. <i>Lancet, The</i> , 2005 , 366, 1829-31	40	32
49	A novel common variant -181 G insertion in the promoter of the gene for phospholipid transfer protein. <i>Atherosclerosis</i> , 2005 , 180, 211-3	3.1	
48	Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetologia</i> , 2005 , 48, 2482-5	10.3	47
47	Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. <i>Journal of Lipid Research</i> , 2004 , 45, 1069-76	6.3	42
46	Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2004 , 21, 901-5	3.5	17
45	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. <i>Kidney International</i> , 2004 , 65, 1790-4	9.9	125
44	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. <i>Lancet, The</i> , 2004 , 364, 685-96	40	2928
43	The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. <i>Atherosclerosis</i> , 2003 , 167, 243-55	3.1	76

42	Problems of reporting genetic associations with complex outcomes. <i>Lancet, The</i> , 2003 , 361, 865-72	4.0	1025
41	Human cytomegalovirus seropositivity is associated with impaired vascular function. <i>Circulation</i> , 2003 , 108, 678-83	16.7	93
40	The effects of hormone replacement therapy on endothelial function in women with Turner's syndrome. <i>Clinical Endocrinology</i> , 2002 , 56, 615-20	3.4	13
39	Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. <i>Diabetic Medicine</i> , 2002 , 19, 201-11	3.5	81
38	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 - 1997/1999. <i>Diabetologia</i> , 2002 , 45, 1362-71	10.3	26
37	C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. <i>Diabetes Care</i> , 2002 , 25, 1813-7	14.6	51
36	Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. <i>Atherosclerosis</i> , 2002 , 163, 363-9	3.1	38
35	Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. <i>Diabetes</i> , 2002 , 51, 1949-56	0.9	116
34	A noninvasive measure of baroreflex sensitivity without blood pressure measurement. <i>American Heart Journal</i> , 2002 , 143, 441-7	4.9	26
33	Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. <i>Diabetes</i> , 2002 , 51, 3300-5	0.9	51
32	Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. <i>Diabetologia</i> , 2001 , 44 Suppl 2, S46-53	10.3	60
31	Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. <i>Diabetes</i> , 2001 , 50, 652-9	0.9	55
30	The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in type 1 diabetic patients and the general population. <i>Diabetes Care</i> , 2001 , 24, 1108-14	14.6	104
29	Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2499-504	5.6	36
28	Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1814-20	15.1	71
27	Cross sectional study of differences in coronary artery calcification by socioeconomic status. <i>BMJ: British Medical Journal</i> , 2000 , 321, 1262-3		12
26	Status report of lipid-lowering trials in diabetes. <i>Current Opinion in Lipidology</i> , 2000 , 11, 621-6	4.4	9
25	Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. <i>Diabetologia</i> , 2000 , 43, 1353-9	10.3	19

24	The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 2160-7	15.1	107
23	Coronary calcification in heart transplants. <i>European Heart Journal</i> , 1999 , 20, 1515	9.5	
22	Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. <i>Diabetic Medicine</i> , 1999 , 16, 41-8	3.5	49
21	The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. <i>Diabetic Medicine</i> , 1999 , 16, 35-40	3.5	40
20	Confirmation needed for genes for hypertension. <i>Lancet, The</i> , 1999 , 353, 1200-1	4.0	15
19	Socio-economic status and blood pressure: an overview analysis. <i>Journal of Human Hypertension</i> , 1998 , 12, 91-110	2.6	288
18	Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the health survey for England. <i>Social Science and Medicine</i> , 1998 , 47, 1773-80	5.1	32
17	Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. <i>Diabetic Medicine</i> , 1998 , 15, 418-26	3.5	45
16	Blood pressure screening, management and control in England: results from the health survey for England 1994. <i>Journal of Hypertension</i> , 1998 , 16, 747-52	1.9	222
15	Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. <i>Journal of Hypertension</i> , 1997 , 15, 1063-8	1.9	51
14	Taking the V out of genes V environment. <i>Journal of Human Hypertension</i> , 1997 , 11, 401-4	2.6	1
13	Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker. <i>BMJ: British Medical Journal</i> , 1997 , 314, 1164-8		33
12	Does Treating Hyperlipidaemia with Medication Prevent Complications?241-255		
11	Reinfection with SARS-CoV-2: outcome, risk factors and vaccine efficacy in a Scottish cohort		1
10	Evaluation of stratify and shields as a policy option for ending the COVID-19 lockdown in the UK		9
9	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study		3
8	Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study		10
7	Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland		7

6	Trajectory of COVID-19 epidemic in Europe		6
5	Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen		2
4	Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households		21
3	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study		1
2	Efficacy of COVID-19 vaccination in individuals designated as clinically extremely vulnerable in Scotland. <i>F1000Research</i> ,10, 663	3.6	0
1	Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study		1